On April 16, 2026 Bold Therapeutics, a clinical-stage biopharmaceutical company that was founded to develop and commercialize novel metallotherapeutics, reported new data highlighting the ability of its lead asset, BOLD-100, to demonstrate protective effects against chemotherapy-induced peripheral neuropathy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BOLD-100 is a first-in-class, ruthenium-based anticancer agent in Phase 2 clinical development for advanced gastrointestinal (GI) cancers in combination with the chemotherapy regimen FOLFOX. BOLD-100 plus FOLFOX improves overall survival and progression-free survival in patients, including advanced colon (mCRC), gastric (GC), and bile duct cancers (BTC). While FOLFOX is a standard-of-care therapy for GI cancers, its clinical utility is limited by acute and chronic peripheral neuropathies which present in the majority of patients. Remarkably, in the ongoing Phase 2 development of BOLD-100, significantly lower than expected incidence of oxaliplatin-induced peripheral neuropathy (OIPN) was observed in patients treated with BOLD-100 plus FOLFOX. Compared to FOLFOX alone historical benchmarks, BOLD-100 plus FOLFOX any-grade neuropathy was:

Colorectal Cancer; 14% vs 53% benchmark
Biliary tract cancer; 35% vs 58% benchmark
Gastric Cancer; 19% vs 63% benchmark
"These clinical findings are promising given the prevalence of peripheral neuropathy among patients undergoing chemotherapy," said Mark Bazett, PhD, Senior Director of Preclinical Development. "The potential to improve patient outcomes while simultaneously improving quality of life is a key differentiating characteristic of BOLD-100. Our upcoming AACR (Free AACR Whitepaper) presentation validates these important results in a range of preclinical models, and provides mechanistic understanding."

Bold Therapeutics will be attending the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual meeting later this month in San Diego from April 17-22, where they will present advanced in vivo and in vitro preclinical modelling of BOLD-100’s neuroprotection, along with mechanism of action data.

Abstract Title: Clinical-stage Anticancer Agent BOLD-100 Demonstrates Protective Effects Against Chemotherapy-Induced Peripheral Neuropathy
Session Time: April 21, 2:00 PM – 5:00 PM
Location: Poster Section 14; Poster Board 11
Presentation Number: 5753

Abstract link: View Source

Bold Therapeutics is currently advancing BOLD-100 through a global Phase 2 randomized controlled trial across sites in Canada, European Union, and South Korea. This trial is investigating BOLD-100’s anticancer efficacy but also includes important quality of life questionnaires focused on its neuroprotective potential. Please visit ClinicalTrials.gov for more information (NCT04421820).

(Press release, Bold Therapeutics, APR 16, 2026, View Source [SID1234664444])

On April 16, 2026 Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, reported that it has established a licensing and commercialization agreement with a strategic business partner ("the partner") in Malaysia for its Denosumab biosimilar products MAILISHU (a biosimilar of Prolia) and MAIWEIJIAN (a biosimilar of Xgeva) ("the products"). Under the agreement, the partner is responsible for the registration and commercialization of the products in Malaysia, while Mabwell is responsible for the development, production and commercial supply for the products.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Malaysia has a population of approximately 35.97 million, with a GDP at a leading level in Southeast Asia. As a full member of PIC/S, Malaysia boasts the most mature and well-regulated pharmaceutical regulatory framework in the ASEAN region. In terms of the pharmaceutical market, Malaysia’s market size stood at approximately USD 3.4 billion in 2025, maintaining a compound annual growth rate of about 6%, indicating big market potential.

Mr. Huiguo Hu, Board Member, Senior Vice President and Board Secretary of Mabwell, said, "We are delighted to see that we have reached a collaboration on denosumab in another ASEAN country. Malaysia has an internationally aligned regulatory environment, strong regional recognition and significant space for development. This collaboration will further deepen Mabwell’s presence in the ASEAN market. We look forward to rapidly advancing the product’s local registration and commercialization with our partner’s strong commercial capabilities, bring high-quality, affordable treatment options to more patients in the region."

(Press release, Mabwell Biotech, APR 16, 2026, View Source [SID1234664443])

On April 16, 2026 SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, reported that the Mount Sinai Health System, one of the leading academic health systems in the United States, will adopt the AI-powered SOPHiA DDM Platform to advance cancer research and enhance genomic testing capabilities.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mount Sinai, a National Cancer Institute-designated Comprehensive Cancer Center in New York City, supports care for more than 4,000 oncology patients annually. Mount Sinai’s Molecular Pathology team will leverage SOPHiA DDM to strengthen next-generation sequencing (NGS) capabilities for blood cancers and solid tumors. The Platform is designed to enable detection and interpretation of a wide range of complex genomic variants while improving operational efficiency by consolidating critical steps in the analysis pipeline and reducing manual interpretation time.

By combining Mount Sinai’s clinical excellence with SOPHiA DDM’s advanced AI-powered analytics, the hospital will be equipped to interpret complex genomic datasets at scale and optimize laboratory resources, enabling teams to focus on direct patient care.

Jane Houldsworth, Ph.D., Director of Molecular Oncology Pathology of the Mount Sinai Health System, said: "The collaboration between Mount Sinai and SOPHiA GENETICS reinforces our commitment to scientific innovation by integrating powerful digital tools into our workflows to support high-quality, data-driven cancer care. Leveraging SOPHiA DDM has enabled us to reduce hands-on analysis time and improve our testing turnaround times, enabling our clinicians to provide better patient care."

John Carey, Managing Director, North America, SOPHiA GENETICS, said: "Mount Sinai is widely regarded as one of the world’s leading centers for cancer research and was recently ranked No. 1 globally among health care institutions in the Nature AI Index, underscoring its leadership in artificial intelligence and data-driven innovation. We are honored to support their teams with an AI-native platform and global network designed to deliver faster results, greater operational efficiency, and deeper genomic understanding to help shape the future of precision oncology."

By utilizing the SOPHiA DDM for Blood Cancers and SOPHiA DDM for Solid Tumors applications, Mount Sinai joins a growing network of more than 990 global institutions using SOPHiA GENETICS’ decentralized platform to accelerate precision medicine. This collaboration underscores SOPHiA GENETICS’ mission to democratize data-driven medicine, delivering scalable, cloud-native solutions that empower healthcare institutions to expand access to advanced genomic testing and improve patient outcomes worldwide.

The collaboration was announced from the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting in San Diego. Learn more by connecting with SOPHiA GENETICS at AACR (Free AACR Whitepaper) booth #4248 from April 17 – 22, 2026.

(Press release, Mount Sinai Hospital, APR 16, 2026, View Source [SID1234664442])

On April 16, 2026 Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, reported Dave Lennon, PhD, President and CEO, will participate in a virtual fireside chat as part of the Jones Trading Post-AACR Fireside Chat Series on Thursday, April 23, 2026, at 3 PM ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the event can be accessed by visiting the Whitehawk Therapeutics IR website and will be available for replay for approximately 30 days following the event.

(Press release, Whitehawk Therapeutics, APR 16, 2026, View Source [SID1234664441])

On April 16, 2026 Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") reported the appointment of two renowned oncologists to its scientific advisory board: Dr. Michael Smylie and Dr. Jonathan Trites.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Michael Smylie is a leading medical oncologist at the Cross Cancer Institute in Edmonton and a clinical professor at the University of Alberta, renowned for his transformative work in melanoma research. He played a key role as a contributing investigator and co-author in the landmark CheckMate clinical trials–specifically CheckMate 067. This study is hailed as a turning point in oncology, as it proved that combining immunotherapy drugs could lead to long-term survival for patients with advanced melanoma, a condition once considered a terminal diagnosis.

His work on the long-term outcomes and quality-of-life data from these trials has helped establish the current international standard of care, moving the needle from short-term treatment to the possibility of decade-long remission for many.

Dr. Jonathan Trites is a head and neck oncologic and reconstructive surgeon based at the Queen Elizabeth II Health Sciences Centre in Halifax. As an Associate Professor at Dalhousie University, he has been a key figure in research advancing surgical techniques and outcomes for complex head and neck cancers.

Dr. Trites’s work primarily focuses on improving the precision and functional outcomes of cancer surgeries. He is a leader in using minimally invasive techniques for tumors of the upper aerodigestive tract. His research has demonstrated that Transoral Laser Microsurgery (TLM) is a viable option for advanced-stage glottic cancer, achieving high rates of laryngeal preservation and excellent functional outcomes. He has also published significant data on various squamous cell carcinomas, including early-stage laryngeal cancer and oropharyngeal cancer.

Sona’s Chief Medical Officer, Dr. Carman Giacomantonio, commented, "I am excited to have Dr. Smylie and Dr. Trites join our scientific advisory board. I have had the privilege of working closely with both gentlemen over the past many years and have a tremendous amount of respect for the experience and wisdom they bring to our table. The clinical course we are embarking upon is truly pioneering. Both Dr. Trites and Dr. Smylie have been pioneers throughout their careers in their respective fields, giving me and my team a tremendous amount confidence as we plan and begin to execute our clinical course going forward."

(Press release, Sona Nanotech, APR 16, 2026, View Source [SID1234664440])